Endospan Ltd.

Endospan Ltd. is a biotechnology and medical devices startup that is revolutionizing the field of endovascular aortic arch repair with its innovative NEXUS® Aortic Arch Stent Graft System. This CE-approved off-the-shelf branched endovascular aortic arch system is designed to address a wide range of aortic pathologies, including arch aneurysms, thoracic dissections, and PAU, overcoming the specific challenges of the aortic arch anatomy. The NEXUS® “Dock and Lock” modular system offers stable and secured anatomical anchoring and atraumatic sealing in a wide range of anatomies. Founded in 2009 and headquartered in Herzlia, Israel, Endospan is a pioneer in the endovascular repair of aortic arch disease. The company's NEXUS® Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark, catering to underserved patients diagnosed with dilative lesions in or near the aortic arch. This innovation is particularly significant as it provides a minimally invasive alternative for patients who would otherwise undergo open-chest surgery, with its associated invasiveness, risks, lengthy hospitalization periods, and prolonged recuperation. Endospan's groundbreaking approach has the potential to significantly impact the medical field and improve patient outcomes. With its focus on addressing unmet medical needs and enhancing the standard of care for aortic arch disease patients, Endospan presents a compelling opportunity for investment in the biotechnology and healthcare sectors. For additional information about Endospan, visit their website at www.endospan.com.